Cancer Letters
Volume 284, Issue 1 , Pages 1-6 , 18 October 2009

Resveratrol and chemoprevention

  • Shyamal K. Goswami

      Affiliations

    • Present address: School of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
    • ,
  • Dipak K. Das

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 860 679 3687; fax: +1 860 679 4606.

Received 19 June 2008 ,Revised 29 January 2009 ,Accepted 29 January 2009.

References 

  1. Flora SD, Quaglia A, Bennicelli C, Vercelli M. The epidemiological revolution of the 20th century. FASEB J. 2005;19:892–897
  2. Russo GL. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem. Pharmacol. 2007;74:533–544
  3. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc. 1976;35:1332–1338
  4. Kwon KH, Barve A, Yu S, Huang MT, Kong ANT. Cancer chemoprevention by phytochemicals: potential molecular targets, biomarkers and animal models. Acta Pharmacol. Sin. 2007;9:1409–1421
  5. De Flora S, Ferguson LR. Overview of mechanisms of cancer chemopreventive agents. Mutat. Res. 2005;59:8–15
  6. Kumar N, Shibata D, Helm J, Coppola D, Malafa M. Green tea polyphenols in the prevention of colon cancer. Front. Biosci. 2007;12:2309–2315
  7. Johnson IT. Phytochemicals and cancer. Proc. Nutr. Soc. 2007;66:207–215
  8. Li Y, Fang H, Xu W. Recent advance in the research of flavonoids as anticancer agents. Mini Rev. Med. Chem. 2007;7:7663–7678
  9. Liu RH. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J. Nutr. 2004;134:3479S–3485S
  10. Jeong WS, Jun M, Kong AN. Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid. Redox. Signal. 2006;8:99–106
  11. Takaoka MJ. Of the phenolic substances of white hellebore (Veratrum grandiflorum Loes. fil.). J. Faculty Sci. Hokkaido Imperial University. 1999;7:8–9
  12. Nonomura S, Kanagawa H, Makimoto A. Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-jo-kon (Polygonum cuspidatum Sieb. et Zucc.). Yakugaku Zasshi. 1963;83:988–990
  13. Richard JL. Coronary risk factors The French paradox. Arch. Mal. Coeur. Vaiss. 1987;17–21
  14. Kopp P. Resveratrol a phytoestrogen found in red wine a possible explanation for the conundrum of the ’French paradox’. Eur. J. Endocrinol. 1998;138:619–620
  15. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta. 1995;235:207–219
  16. Fitzpatrick DF, Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing activity of wine and other grape products. Am. J. Physiol. 1993;265:H774–778
  17. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. Lancet. 1993;341:1103–1104
  18. Asensi M, Medina I, Ortega A, Carretero J, Baño MC, Obrador E, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 2002;33:387–398
  19. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004;32:1377–1382
  20. Jannin B, Menzel M, Berlot JP, Delmas D, Lançon A, Latruffe N. Transport of resveratrol a cancer chemopreventive agent to cellular targets: plasmatic protein binding and cell uptake. Biochem. Pharmacol. 2004;68:113–118
  21. Kaldas MI, Walle UK, Walle T. Resveratrol transport and metabolism by human intestinal Caco-2 cells. J. Pharm. Pharmacol. 2003;55:307–312
  22. Das DK, Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol. Interv. 2006;6:36–47
  23. Rimando AM, Cuendet M, Desmarchelier C, Mehta RG, Pezzuto JM, Duke SO. Cancer chemopreventive and antioxidant activities of pterostilbene a naturally occurring analogue of resveratrol. J. Agric. Food Chem. 2002;50:3453–3457
  24. Wolter F, Clausnitzer A, Akoglu B, Stein J. Piceatannol a natural analog of resveratrol inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J. Nutr. 2002;132:298–302
  25. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer. 2002;86:774–778
  26. Shin NH, Ryu SY, Choi EJ, Kang SH, Chang IM, Min KR, et al. Oxyresveratrol as the potent inhibitor on dopa oxidase activity of mushroom tyrosinase. Biochem. Biophys. Res. Commun. 1998;243:801–803
  27. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol a natural product derived from grapes. Science. 1997;275:218–220
  28. Carbó N, Costelli P, Baccino FM, López-Soriano FJ, Argilés JM. Resveratrol a natural product present in wine decreases tumour growth in a rat tumour model. Biochem. Biophys. Res. Commun. 1999;254:739–743
  29. Wadsworth TL, Koop DR. Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. Biochem. Pharmacol. 1999;57:941–949
  30. Park JW, Choi YJ, Jang MA, Lee YS, Jun DY, Suh SI, et al. Chemopreventive agent resveratrol a natural product derived from grapes reversibly inhibits progression through S and G2 phases of the cell cycle in U937 cells. Cancer Lett. 2001;163:43–49
  31. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology. 2000;141:3657–3667
  32. Ray PS, Maulik G, Cordis GA, Bertelli AA, Bertelli A, Das DK. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic. Biol. Med. 1999;27:160–169
  33. Miloso M, Bertelli AA, Nicolini G, Tredici G. Resveratrol-induced activation of the mitogen-activated protein kinases ERK1 and ERK2 in human neuroblastoma SH-SY5Y cells. Neurosci. Lett. 1999;264:141–144
  34. Fontecave M, Lepoivre M, Elleingand E, Gerez C, Guittet O. Resveratrol a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 1998;421:277–279
  35. Tsai SH, Lin-Shiau SY, Lin JK. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol. 1999;126:673–680
  36. Zheng J, Ramirez VD. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br. J. Pharmacol. 2000;130:1115–1123
  37. Stewart JR, Christman KL, O’Brian CA. Effects of resveratrol on the autophos-phorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. Biochem. Pharmacol. 2000;60:1355–1359
  38. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B activator protein-1 and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 2000;164:6509–6519
  39. Casper RF, Quesne M, Rogers IM, Shirota T, Jolivet A, Milgrom E, et al. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol. Pharmacol. 1999;56:784–790
  40. Ciolino HP, Yeh GC. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol. Pharmacol. 1999;56:760–767
  41. Subbaramaiah K, Michaluart P, Chung WJ, Tanabe T, Telang N, Dannenberg AJ. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann. NY Acad. Sci. 1999;889:214–223
  42. Granados-Soto V. Pleiotropic effects of resveratrol. Drug News Perspect. 2003;16:299–307
  43. Srivastava R, Ratheesh A, Gude RK, Rao KV, Panda D, Subrahmanyam G. Resveratrol inhibits type II phosphatidylinositol 4-kinase: a key component in pathways of phosphoinositide turn over. Biochem. Pharmacol. 2005;70:1048–1055
  44. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 2005;280:17187–17195
  45. Regev-Shoshani G, Shoseyov O, Kerem Z. Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4. Biochem. Biophys. Res. Commun. 2004;323:668–673
  46. Vella F, Ferry G, Delagrange P, Boutin JA. NRH: quinone reductase 2: an enzyme of surprises and mysteries. Biochem. Pharmacol. 2005;71:1–12
  47. Yang S, Irani K, Heffron SE, Jurnak F, Meyskens Jr FL. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther. 2005;4:1923–1935
  48. Lin HY, Lansing L, Merillon JM, Davis FB, Tang HY, Shih A, et al. Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB J. 2006;20:1742–1744
  49. Hambrock A, de Oliveira Franz CB, Hiller S, Grenz A, Ackermann S, Schulze DU, et al. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner. J. Biol. Chem. 2007;282:3347–3356
  50. Singh NP, Hegde VL, Hofseth LJ, Nagarkatti M, Nagarkatti P. Resveratrol (trans-3, 5, 4′-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol. Pharmacol. 2007;72:1508–1521
  51. Gledhill JR, Montgomery MG, Leslie AG, Walker JE. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc. Natl. Acad. Sci. USA. 2007;104:13632–13637
  52. Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V, Della Ragione F. Resveratrol: from basic science to the clinic. Cell Cycle. 2007;6:2495–2510
  53. Acconcia F, Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett. 2006;238:1–14
  54. Limer JL, Speirs V. Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res. 2004;6:119–127
  55. Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol a polyphenolic compound found in grapes and wine is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA. 1997;94:14138–14143
  56. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 2001;61:7456–7463
  57. Turner RT, Evans GL, Zhang M, Maran A, Sibonga JD. Is resveratrol an estrogen agonist in growing rats. Endocrinology. 1999;140:50–54
  58. Lu R, Serrero G. Resveratrol a natural product derived from grape exhibits antiestro-genic activity and inhibits the growth of human breast cancer cells. J. Cell. Physiol. 1999;179:297–304
  59. Vyas S, Asmerom Y, De León DD. Resveratrol regulates insulin-like growth factor-II in breast cancer cells. Endocrinology. 2005;146:4224–4233
  60. Choi HK, Yang JW, Kang KW. Bifunctional effect of resveratrol on the expression of ErbB2 in human breast cancer cell. Cancer Lett. 2006;242:198–206
  61. Gougelet A, Mueller SO, Korach KS, Renoir JM. Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha. J. Steroid Biochem. Mol. Biol. 2007;104:110–122
  62. Su JL, Yang CY, Zhao M, Kuo ML, Yen ML. Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J. Biol. Chem. 2007;282:19385–19398
  63. Le Corre L, Fustier P, Chalabi N, Bignon YJ, Bernard-Gallon D. Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines. Clin. Chim. Acta. 2004;344:15–21
  64. Levenson AS, Svoboda KM, Pease KM, Kaiser SA, Chen B, Simons LA, et al. Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002;62:4419–4426
  65. Sareen D, Darjatmoko SR, Albert DM, Polans AS. Mitochondria calcium and calpain are key mediators of resveratrol-induced apoptosis in breast cancer. Mol. Pharmacol. 2007;72:1466–1475
  66. Tang HY, Shih A, Cao HJ, Davis FB, Davis PJ, Lin HY. Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol. Cancer Ther. 2006;5:2034–2042
  67. Wang Y, Lee KW, Chan FL, Chen S, Leung LK. The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells. Toxicol. Sci. 2006;92:71–77
  68. Watson CS, Alyea RA, Jeng YJ, Kochukov MY. Nongenomic actions of low concentration estrogens and xenoestrogens on multiple tissues. Mol. Cell. Endocrinol. 2007;274:1–7
  69. Chen JQ, Yager JD, Russo J. Regulation of mitochondrial respiratory chain structure and function by estrogens/estrogen receptors and potential physiological/ pathophysiological implications. Biochim. Biophys. Acta. 2005;1746:1–17
  70. Pietras RJ, Levin ER, Szego CM. Estrogen receptors and cell signaling. Science. 2005;310:51–53
  71. Jacob J, Sebastian KS, Devassy S, Priyadarsini L, Farook MF, Shameem A, et al. Membrane estrogen receptors: genomic actions and post transcriptional regulation. Mol. Cell. Endocrinol. 2006;246:34–41
  72. Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK, et al. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun. 2003;309:1017–1026
  73. Bianco NR, Chaplin LJ, Montano MM. Differential induction of quinone reductase by phytoestrogens and protection against oestrogen-induced DNA damage. Biochem. J. 2005;385:279–287
  74. Hebbar V, Shen G, Hu R, Kim BR, Chen C, Korytko PJ, et al. Toxicogenomics of resveratrol in rat liver. Life Sci. 2005;76:2299–2314
  75. Yang S, Irani K, Heffron SE, Jurnak F, Meyskens FL. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther. 2005;4:1923–1935
  76. Azmi AS, Bhat SH, Hanif S, Hadi SM. Plant polyphenols mobilize endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for anticancer properties. FEBS Lett. 2006;580:533–538
  77. Wang S, Wang X, Yan J, Xie X, Fan F, Zhou X, et al. Resveratrol inhibits proliferation of cultured rat cardiac fibroblasts: correlated with NO-cGMP signaling pathway. Eur. J. Pharmacol. 2007;567:26–35
  78. Woo JH, Lim JH, Kim YH, Suh SI, Min DS, Chang JS, et al. Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene. 2004;23:1845–1853
  79. Rodrigue CM, Porteu F, Navarro N, Bruyneel E, Bracke M, Romeo PH, et al. The cancer chemopreventive agent resveratrol induces tensin a cell–matrix adhesion protein with signaling and antitumor activities. Oncogene. 2005;5:3274–3284
  80. Kotha A, Sekharam M, Cilenti L, Siddiquee K, Khaled A, Zervos AS, et al. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther. 2006;5:621–629
  81. Alkhalaf M, Jaffal S. Potent antiproliferative effects of resveratrol on human osteosarcoma SJSA1 cells: novel cellular mechanisms involving the ERKs/p53 cascade. Free Radic. Biol. Med. 2006;41:318–325
  82. Shimizu T, Nakazato T, Xian MJ, Sagawa M, Ikeda Y, Kizaki M. Resveratrol induces apoptosis of human malignant B cells by activation of caspase-3 and p38 MAP kinase pathways. Biochem. Pharmacol. 2006;71:742–750
  83. Delmas D, Rébé C, Micheau O, Athias A, Gambert P, Grazide S, et al. Redistribution of CD95 DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene. 2004;23:8979–8986
  84. Heiss EH, Schilder YD, Dirsch VM. Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells. J. Biol. Chem. 2007;282:26759–26766
  85. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2007;109:2293–2302
  86. Ulrich S, Loitsch SM, Rau O, Knethen von A, Brüne B, Schubert-Zsilavecz M, et al. Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res. 2006;66:7348–7354
  87. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol. Cancer Ther. 2005;4:1465–1474
  88. Cao Z, Fang J, Xia C, Shi X, Jiang BH. trans-345’-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin. Cancer Res. 2004;10:5253–5263
  89. Yang S, Meyskens FL. Alterations in activating protein 1 composition correlate with phenotypic differentiation changes induced by resveratrol in human melanoma. Mol. Pharmacol. 2005;67:298–308
  90. El-Mowafy AM. Resveratrol activates membrane-bound guanylyl cyclase in coronary arterial smooth muscle: a novel signaling mechanism in support of coronary protection. Biochem. Biophys. Res. Commun. 2002;291:218–2124
  91. Mattson MP, Son TG, Camandola S. Viewpoint: mechanisms of action and therapeutic potential of neurohormetic phytochemicals. Dose Resp. 2007;5:174–186
  92. Mattson MP. Dietary factors hormesis and health. Age. Res. Rev. 2008;7:1–7
  93. Jiang WJ. Sirtuins: novel targets for metabolic disease in drug development. Biochem. Biophys. Res. Commun. 2008;73:341–344

PII: S0304-3835(09)00084-6

doi: 10.1016/j.canlet.2009.01.041

Cancer Letters
Volume 284, Issue 1 , Pages 1-6 , 18 October 2009

Article Tools